BE Study of Bilayer Combination of Gemigliptin/Rosuvastatin 50/20mg in Comparison to Monolayer Combination.

NCT03867942 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2
Dyslipidemias

Interventions

DRUG: Monolayer group
DRUG: Bilayer group

Sponsor

LG Chem